Britain and America have announced a landmark bilateral deal that will preserve zero import taxes on UK drug shipments being sold in the American market.
Agreement Details of the Accord
As part of the deal, the UK has pledged to raise funding on medicines through the National Health Service (NHS). This pledge ensures that import taxes on these crucial goods will stay at zero for a duration of three years.
This agreement comes after previous warnings to hike tariffs on branded drug imports, with potential rates mentioned as high as double the cost.
"This deal with the United Kingdom bolsters the worldwide climate for cutting-edge drugs and introduces much-needed balance to American-British pharmaceutical trade," a release noted.
Economic Impact
Pharmaceuticals represent one of the Britain's biggest goods shipped to the United States, which is by far the biggest destination for leading UK drugmakers.
Trade data show that in the 12 months prior to the third quarter, the UK exported pharmaceutical products valued at £11.1bn to the US. This value made up 17.4% of British export trade in that period.
"This guarantee safeguards jobs, increases investment and paves the way for the UK to emerge as a international leader for medical research," a government official remarked.
Detailed UK Commitments
The agreement involves several notable pledges from the British government:
- Price Threshold Increase: The UK will lift the price threshold at which it judges new therapies to be too expensive by a quarter.
- Increased NHS Spending: There is a target to double overall NHS spending on treatments from 0.3 percent of GDP to 0.6% over the next decade.
- Rebate Cap: The amount drug companies must pay back to the NHS to control costs will be capped at 15%. Last year, refunds exceeded 20%.
Recent Tensions
This agreement follows a protracted row between the drug companies and the ministers over spending levels and regulatory access.
The disagreement were exacerbated by claims that US customers were paying a premium for the same drugs than people in the other developed nations.
In recent months, several major manufacturing plans in the UK have been paused or abandoned, while substantial expansions have been announced toward American operations.
The Science Minister acknowledged that the NHS needed to invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a percentage of its overall budget over the previous ten-year period.
